If you or a family member developed laparoscopic gastric surgery with a high dose of laparoscopy with a Gadolinium contrast dye, although a new method of chelation has not yet been discovered, you can file a medical malpractice claim. Known as “diethydrotestosterone therapy,” (DHT) was originally recommended to patients with prostate cancer undergoing surgery. The procedure is performed by injecting a very small amount of a chemical called DHT into the patient’s abdomen. The drug has been shown to disrupt testosterone production in patients with enlarged prostate ducts. In the past, most medical professionals approved of this treatment; however, recent studies have questioned the safety and continued use of DHT for this purpose.
Contrast dye Lawsuit
According to medical experts, DHT does not pass through the stomach or enter the bloodstream. Instead, it diffuses into the body’s lymphatic system where it attacks healthy tissue. Studies indicate that men who were administered large doses of mri dye while undergoing a procedure involving their prostate reported higher levels of fatigue, persistent headaches, nausea, vomiting, and pain in the abdominal region. A number of patients who did undergo malpractice injuries due to DHT-related exhaustion later developed prostate cancer. Unfortunately, these cancer cases are not publicized because the victims could not obtain a settlement from the hospital or doctors who employed this method.
There are other examples of malpractice related to the use of contrast dye agents.
An Orlando, Florida resident was injected with excessive amounts of caffeine and died within a month of being injected. Another case in Southern California involves the wrongful death of a woman who died of mesothelioma due to the inhalation of unusually-collected and toxic contrast dye agents. Her family is seeking millions of dollars in damages because the manufacturers of these agents, GlaxoSmithKline, and Sharp Imaging failed to warn them of the risks associated with their product. Another lawsuit filed against GlaxoSmithKline involved the use of potassium sorbate as an intravenous agent for patients with heart disease.
Malpractice cases involving medical products or treatments with known side effects are also quite common.
The most common side effect from the administration of contrast dye is an allergic reaction to the dye or its components. From this viewpoint, it seems that it is GlaxoSmithKline’s responsibility to notify patients about the possible risks associated with using their product and informing them about the potential side effects of using the dye itself.
FDA received much public complaint regarding various products, including some that contained DMSA chelation.
While they acknowledged the product’s benefits, they also admitted the possibility of causing harm to patients. At one point, the FDA proposed to ban all products containing DMSA chelation and asked drug manufacturers to change the concentration of the chemical in their products if they could not guarantee the absence of an allergic reaction. This request was never acted upon by the FDA.
Other lawsuits have been brought against GlaxoSmithKline including one brought by a U.S. plaintiff who died as a direct result of the deficiency of glutathione in her bloodstream.
Although the FDA has acknowledged the relationship between DMSA and the development of gout, they are not sure of the long term effects of the chemical. There have been studies in the U.S. courts involving individuals who suffered acute renal failure, cardiovascular collapse, and other kidney related complications from the deficiency of glutathione. There are many more lawsuits like these in pending by U.S. plaintiffs.
